{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:30:34Z","timestamp":1707525034203},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,11]]},"DOI":"10.7759\/cureus.38867","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T09:45:05Z","timestamp":1683798305000},"source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Bebtelovimab Therapy in Patients With Solid Organ Transplantation With Mild and Moderate COVID-19"],"prefix":"10.7759","author":[{"given":"Rohan","family":"Kapur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Feola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhay","family":"Dhand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001234","article-title":"COVID-19 in solid organ transplantation: results of the national COVID cohort collaborative","volume":"7","author":"Vinson AJ","year":"2021","unstructured":"Vinson AJ, Agarwal G, Dai R, et al.. COVID-19 in solid organ transplantation: results of the national COVID cohort collaborative. Transplant Direct. 2021, 7:e775. 10.1097\/TXD.0000000000001234","journal-title":"Transplant Direct"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020050639","article-title":"COVID-19 infection in kidney transplant recipients: disease incidence and clinical outcomes","volume":"31","author":"Elias M","year":"2020","unstructured":"Elias M, Pievani D, Randoux C, et al.. COVID-19 infection in kidney transplant recipients: disease incidence and clinical outcomes. J Am Soc Nephrol. 2020, 31:2413-23. 10.1681\/ASN.2020050639","journal-title":"J Am Soc Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.09.006","article-title":"Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe","volume":"98","author":"Jager KJ","year":"2020","unstructured":"Jager KJ, Kramer A, Chesnaye NC, et al.. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020, 98:1540-8. 10.1016\/j.kint.2020.09.006","journal-title":"Kidney Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4509","article-title":"Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study","volume":"371","author":"Pastor-Barriuso R","year":"2020","unstructured":"Pastor-Barriuso R, P\u00e9rez-G\u00f3mez B, Hern\u00e1n MA, et al.. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. BMJ. 2020, 371:m4509. 10.1136\/bmj.m4509","journal-title":"BMJ"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003670","article-title":"Outcomes of COVID-19 in solid organ transplant recipients: a propensity-matched analysis of a large research network","volume":"105","author":"Hadi YB","year":"2021","unstructured":"Hadi YB, Naqvi SF, Kupec JT, Sofka S, Sarwari A. Outcomes of COVID-19 in solid organ transplant recipients: a propensity-matched analysis of a large research network. Transplantation. 2021, 105:1365-71. 10.1097\/TP.0000000000003670","journal-title":"Transplantation"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40472-022-00357-2","article-title":"COVID-19 and solid organ transplantation: role of anti-SARS-CoV-2 monoclonal antibodies","volume":"9","author":"Dhand A","year":"2022","unstructured":"Dhand A, Razonable RR. COVID-19 and solid organ transplantation: role of anti-SARS-CoV-2 monoclonal antibodies. Curr Transplant Rep. 2022, 9:26-34. 10.1007\/s40472-022-00357-2","journal-title":"Curr Transplant Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2201933","article-title":"Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2","volume":"386","author":"Takashita E","year":"2022","unstructured":"Takashita E, Kinoshita N, Yamayoshi S, et al.. Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2. N Engl J Med. 2022, 386:1475-7. 10.1056\/NEJMc2201933","journal-title":"N Engl J Med"},{"key":"ref8","unstructured":"National Institutes of Health. SARS-CoV-2 variants currently or recently circulating in the United States and their susceptibility to anti-SARS-CoV-2 monoclonal antibodies. (2023). Accessed: April 19, 2023: https:\/\/www.covid19treatmentguidelines.nih.gov\/tables\/variants-and-susceptibility-to-mabs\/."},{"key":"ref9","unstructured":"Fact sheet for healthcare providers. emergency use authorization for bebtelovimab. (2022). Accessed: April 16, 2023: https:\/\/www.fda.gov\/media\/156152\/download."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1101\/2022.03.10.22272100","article-title":"Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19","author":"Dougan M","year":"2022","unstructured":"Dougan M, Azizad M, Chen P, et al.. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. medRxiv. 2022, 10.1101\/2022.03.10.22272100","journal-title":"medRxiv"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13901","article-title":"Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch","volume":"24","author":"Yetmar ZA","year":"2022","unstructured":"Yetmar ZA, Beam E, O'Horo JC, Seville MT, Brumble L, Ganesh R, Razonable RR. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch. Transpl Infect Dis. 2022, 24:e13901. 10.1111\/tid.13901","journal-title":"Transpl Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004278","article-title":"Bebtelovimab for treatment of COVID-19 in ambulatory solid organ transplant recipients","volume":"106","author":"Shertel T","year":"2022","unstructured":"Shertel T, Lange NW, Salerno DM, et al.. Bebtelovimab for treatment of COVID-19 in ambulatory solid organ transplant recipients. Transplantation. 2022, 106:e463-4. 10.1097\/TP.0000000000004278","journal-title":"Transplantation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac517","article-title":"Evaluation of bebtelovimab for treatment of Covid-19 during the SARS-CoV-2 Omicron variant era","volume":"9","author":"McCreary EK","year":"2022","unstructured":"McCreary EK, Kip KE, Collins K, et al.. Evaluation of bebtelovimab for treatment of Covid-19 during the SARS-CoV-2 Omicron variant era. Open Forum Infect Dis. 2022, 9:ofac517. 10.1093\/ofid\/ofac517","journal-title":"Open Forum Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004418","article-title":"COVID-19 outcomes in solid organ transplant recipients who received tixagevimab-cilgavimab prophylaxis and\/or bebtelovimab treatment in a nurse-driven monoclonal antibody program during the Omicron surge","volume":"107","author":"Cochran W","year":"2023","unstructured":"Cochran W, Salto-Alejandre S, Barker L, et al.. COVID-19 outcomes in solid organ transplant recipients who received tixagevimab-cilgavimab prophylaxis and\/or bebtelovimab treatment in a nurse-driven monoclonal antibody program during the Omicron surge. Transplantation. 2023, 107:e60-1. 10.1097\/TP.0000000000004418","journal-title":"Transplantation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac346","article-title":"Comparable outcomes for bebtelovimab and ritonavir-boosted nirmatrelvir treatment in high-risk patients with coronavirus disease-2019 during severe acute respiratory syndrome coronavirus 2 BA.2 Omicron epoch","volume":"226","author":"Razonable RR","year":"2022","unstructured":"Razonable RR, O'Horo JC, Hanson SN, et al.. Comparable outcomes for bebtelovimab and ritonavir-boosted nirmatrelvir treatment in high-risk patients with coronavirus disease-2019 during severe acute respiratory syndrome coronavirus 2 BA.2 Omicron epoch. J Infect Dis. 2022, 226:1683-7. 10.1093\/infdis\/jiac346","journal-title":"J Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16843","article-title":"Use of anti-spike monoclonal antibodies in kidney transplant recipients with COVID-19: efficacy, ethnic and racial disparities","volume":"22","author":"Klein EJ","year":"2022","unstructured":"Klein EJ, Hardesty A, Vieira K, Farmakiotis D. Use of anti-spike monoclonal antibodies in kidney transplant recipients with COVID-19: efficacy, ethnic and racial disparities. Am J Transplant. 2022, 22:640-5. 10.1111\/ajt.16843","journal-title":"Am J Transplant"},{"key":"ref17","unstructured":"Food and Drug Administration. FDA announces bebtelovimab is not currently authorized in any US region. (2022). Accessed: April 10, 2023: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-bebtelovimab-not-currently-authorized-any-us-region."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/154352-outcomes-of-bebtelovimab-therapy-in-patients-with-solid-organ-transplantation-with-mild-and-moderate-covid-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:59:40Z","timestamp":1707508780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/154352-outcomes-of-bebtelovimab-therapy-in-patients-with-solid-organ-transplantation-with-mild-and-moderate-covid-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.38867","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,11]]}}}